194 related articles for article (PubMed ID: 21881888)
21. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
[TBL] [Abstract][Full Text] [Related]
22. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
Fogari R; Zoppi A; Ferrari I; Mugellini A; Preti P; Lazzari P; Derosa G
Horm Metab Res; 2009 Dec; 41(12):893-8. PubMed ID: 19708000
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Dowlatshahi D; Hill MD
Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
[TBL] [Abstract][Full Text] [Related]
24. Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.
Gregori JA; Nuñez JF; Domínguez-Gil A;
Drugs Aging; 2009; 26(7):617-26. PubMed ID: 19655828
[TBL] [Abstract][Full Text] [Related]
25. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension.
de la Sierra A; Munoz A; Arcos E; Lopez JS; Relats J;
Blood Press Suppl; 2004 Dec; 2():5-10. PubMed ID: 15631277
[TBL] [Abstract][Full Text] [Related]
26. Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress.
Arosio E; De Marchi S; Prior M; Rigoni A; Lechi A
J Hypertens; 2005 Oct; 23(10):1923-7. PubMed ID: 16148617
[TBL] [Abstract][Full Text] [Related]
27. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I; Chilvers M; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[TBL] [Abstract][Full Text] [Related]
28. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
29. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.
Elliott WJ
J Hum Hypertens; 1999 Jun; 13(6):413-7. PubMed ID: 10408592
[TBL] [Abstract][Full Text] [Related]
30. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
Larsen K; Hornnes N; Boysen G
Stroke; 2006 Jun; 37(6):1357; author reply 1358. PubMed ID: 16645128
[No Abstract] [Full Text] [Related]
31. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
Dhakam Z; McEniery CM; Yasmin ; Cockcroft JR; Brown MJ; Wilkinson IB
Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of eprosartan.
Gavras I; Gavras H
Pharmacotherapy; 1999 Apr; 19(4 Pt 2):102S-107S. PubMed ID: 10213529
[TBL] [Abstract][Full Text] [Related]
33. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.
Zou Z; Xi GL; Yuan HB; Zhu QF; Shi XY
J Hum Hypertens; 2009 May; 23(5):339-49. PubMed ID: 18987649
[TBL] [Abstract][Full Text] [Related]
34. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Shlyakhto E
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.
Sega R
Blood Press; 1999; 8(2):114-21. PubMed ID: 10451039
[TBL] [Abstract][Full Text] [Related]
36. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Argenziano L; Trimarco B
Curr Med Res Opin; 1999; 15(1):9-14. PubMed ID: 10216806
[TBL] [Abstract][Full Text] [Related]
37. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Levine B
Curr Med Res Opin; 1999; 15(1):25-32. PubMed ID: 10216808
[TBL] [Abstract][Full Text] [Related]
38. Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension.
Cheng-Lai A
Heart Dis; 2002; 4(1):54-9. PubMed ID: 11975834
[TBL] [Abstract][Full Text] [Related]
39. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
Diamond JA; Gharavi A; Roychoudhury D; Machac J; Henzlova MJ; Travis A; Phillips RA
Curr Med Res Opin; 1999; 15(1):1-8. PubMed ID: 10216805
[TBL] [Abstract][Full Text] [Related]
40. Effects of eprosartan on target organ protection.
de la Sierra A
Vasc Health Risk Manag; 2006; 2(1):79-85. PubMed ID: 17319472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
